

Production of Medical Radioisotopes at Oak Ridge National Laboratory

Chris Bryan TRTR/IGORR 2023 – University of Maryland June18-22, 2023

ORNL is managed by UT-Battelle, LLC for the US Department of Energy



US Government sponsored radioisotope production work is supported by various organizations depending upon the isotope





Sites supporting the DOE Isotope Program





Medical radioisotopes originated from ORNL

In 1946, ORNL sent the first official shipment of a medical radioisotope, carbon-14, to a hospital—Barnard Free Skin and Cancer Hospital in St. Louis



The small container of carbon-14 was use for research in cancer studies and was the first peaceful isotope produced from the Manhattan Project.







ORNL produced Radioisotopes

²²⁴Ra/²¹²Pb

• ¹⁸⁸W/¹⁸⁸Re

²²³Ra/²²⁷Th

• ^{166m}Ho

• ²²⁷ Ac	• ²²⁸ Th
---------------------	---------------------

• ²⁵²Cf • ²⁴⁹Bk

- ²²⁵Ac ²⁵⁷Fm
- ¹³³Ba
- ⁶³Ni
- ⁷⁵Se
- ⁸⁹Sr
 - ^{254/253}Es ¹⁷⁰Tm*
 - ^{117m}Sn ²²⁹Th*

• ¹⁴⁷Pm • ^{195m}P†

• 238Pu

• ¹⁹¹Os

• ⁶⁰Co

• 177Lu

• 192|r

- ²²⁹Th
- ¹⁴C
 - ²¹⁰Pb
- ⁸⁵Kr

ORNL also dispenses high-purity ^{238,239,240,242,244}Pu, ²³⁷Np, ²⁴³Am, ⁹⁹Tc, ²⁰⁹Po, ^{233,234,235,238}U, and ^{244,248}Cm from inventory

In production
Production ready
Under development



The production of these radioisotopes is made possible because of the High Flux Isotope Reactor and hot cell processing capabilities at ORNL

W-188 is the parent of medical radioisotope Re-188

- Re-188 is a high energy beta-emitting radioisotope $(t_{1/2} = 17h)$
- The high energy allows for penetration and destruction of targeted tissues
- Low-energy, low-intensity gamma emission is effective for imaging
- Chemically similar to Tc-99 for ease of preparation and targeting
- Available at high specific activity via W-188 generators
- Being studied for Bone Pain Palliation as well as Hematological and Solid Tumors





Sr-89 ($t_{1/2}$ = 50.6 d) Production (beta-emitter)

⁸⁹Sr-produced in HFIR from highly enriched
⁸⁸Sr and intended for bone pain palliation



Anion exchange column



Irradiated pellets

Irradiated pellets



Sn-117m treats arthritis in dogs

- Sn-117m decays via internal conversion with a half life of 13.6 d
- Decays to inert tin and is removed via the lymphatics
- Emits a 159 keV gamma for imaging purposes
- Discrete radiation range, with minimal dose to others
- Could someday be considered for humans





Alpha-emitting isotopes can directly target tumor sites

- Ac-227 is the parent isotope of ²²³Ra (t_{1/2} = 11.4 d), the active pharmaceutical ingredient in Xofigo®
 - Radium has similar chemical behavior to Ca and travels to the bones where it attacks bone metastases, providing pain relief and potentially life extension
 - Higher LET than Sr-89, a beta emitter with similar applications
- Ac-225 has desirable decay characteristics for targeted alpha therapy
 - Emits 5-8 MeV from 4 α particles, cell kill possible with 1 hit
 - 10-day half-life for effective handling logistics
 - Targeting vector required
 - Significant recoil
- **Pb-212** is similar to Ac-225, with a shorter half-life
 - More challenging handling logistics, higher dose rate







HFIR is our workhorse for isotope production



85 MW Thermal Power

Peak Thermal Flux = 2.5 E 15 n/cm²-sec

Peak Fast Flux = 1.2 E 15 n/cm²sec

Light water moderated and cooled

Beryllium reflected

Fuel: AL clad U₃O₈ plates – 9.4 Kg ₂₃₅U

Control – concentric cylinders of EuO

Cycle length: 24.5 days (85 MW operations)

Purpose-built for heavy element production

Element 117 – Tennessine was

discovered using ²⁴⁹Bk from

HFIR



Glenn Seaborg and his colleagues discovered 10 new elements including plutonium. Additionally they identified more than new 100 isotopes. Glenn was the leading advocate for building HFIR as an isotope production reactor to support heavy element research.

"The field of new transuranium elements is entering an era where the participating scientists in this country cannot go much further without some unified national effort... The future progress in this area depends on substantial weighable quantities (say milligrams) of berkelium, californium, and einsteinium..."



Early heavy element production work led to the commercial sale of ²⁵²Cf. HFIR supplies 70% of the world's demand for ²⁵²Cf, which is used as a reactor startup source, and radiography, for the coal and oil industry. HFIR operation forms an irreplaceable cornerstone of this billion dollar industry.



source



HFIR's high flux is due to its fuel and flux trap type design



Irradiation capsule/experiment requirements are rigorous



- Neutronic core interactions
 - Flux tilt, cycle-length reduction, etc...
- Capsule heat removal
- Target material/cladding interactions
- Target material performance
 - Expansion, growth, compound formation, fission gas release, etc...
- Capsule integrity
 - Material certification, weld qualification, internal/external pressure capacity

Radioisotope chemical separation and purification have grown from the heavy element production program



Main dissolution hot cell in the Radiochemical Engineering Development Center (REDC) REDC hot cells are used for curium target fabrication/assembly and irradiated Pu-238 and Cf-252 target dissolution, separation and purification.

ORNL's hot cells and gloveboxes enable unique isotope production

- Hot target fabrication has history at ORNL
 - ORNL has multiple hot cells with this capability.
 - Most are irradiated in smaller rabbit capsules.
 - Some use HFIR hydraulic tube (less than 25d irradiation), while others require multiple cycle irradiations.



Assembly and welding of ²²⁶Ra targets in an ORNL hot cell



Radioisotope Processing Facility (RPF) is a funded project that enables new isotope production plus expanded hot cell and glovebox processing capacity.



Proposed new isotopes possible through RPF

Iridium-192	Strontium-90	Lutetium-177 (сGMP)
Gadolinium-153	Strontium-89 (cGMP)	Carbon-14
Thorium-229	Promethium-147	Phosporus-33





Thank you!



2023 TRTR/IGORR – University of Maryland